Share

Philip Morris International Inc (PM.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 18 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Price-adjusted rating

Neutral

5-Year Return Est.

+41.0%

Includes 2.16% annual net dividend contribution

1. Investment Thesis — Base Case

The question is not whether PMI grows — it is whether a 22.7x forward multiple survives while the American smoke-free engine that justified the re-rating visibly stalls. Combustible price/mix and ex-US IQOS conversion should deliver roughly 7-9% currency-neutral adjusted EPS growth, carrying FY2026's approximate $8.35 midpoint [1][20] toward about $12 by 2031. Against that, a 5% ten-year yield and a 73% payout ratio argue for gradual de-rating toward the 18-19x five-year median [18]. The probable outcome: earnings compound steadily, the multiple leaks, and shareholders collect modest price appreciation plus a reliable dividend.

FY2026 adjusted EPS midpoint near $8.35 compounding around 8% annually implies roughly $12 by 2031.
At 18-19x that figure, equity value lands near $225-235 against $189 today.
Cross-check: roughly $12B free cash flow versus $10B dividends leaves thin room for buybacks.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-14	103
Observed price	2021-10-04	96.3
Observed price	2021-10-16	97.7
Observed price	2021-10-28	94.7
Observed price	2021-11-13	94.3
Observed price	2021-11-21	90.2
Observed price	2021-11-29	87.3
Observed price	2021-12-15	92.7
Observed price	2021-12-23	92.9
Observed price	2022-01-08	99.6
Observed price	2022-01-24	101
Observed price	2022-01-28	104
Observed price	2022-02-17	112
Observed price	2022-02-25	102
Observed price	2022-03-01	102
Observed price	2022-03-13	90.2
Observed price	2022-03-25	92.5
Observed price	2022-04-14	101
Observed price	2022-04-26	103
Observed price	2022-05-08	98.9
Observed price	2022-05-20	101
Observed price	2022-05-28	107
Observed price	2022-06-05	106
Observed price	2022-06-17	98.6
Observed price	2022-06-29	101
Observed price	2022-07-15	89.6
Observed price	2022-07-23	96.1
Observed price	2022-08-12	99.9
Observed price	2022-08-16	101
Observed price	2022-09-05	94.6
Observed price	2022-09-09	97.1
Observed price	2022-09-29	86.1
Observed price	2022-10-07	84.7
Observed price	2022-10-23	87.5
Observed price	2022-10-27	89.5
Observed price	2022-11-16	94.7
Observed price	2022-11-20	96.7
Observed price	2022-12-02	103
Observed price	2022-12-14	102
Observed price	2022-12-18	101
Observed price	2023-01-23	101
Observed price	2023-01-27	104
Observed price	2023-01-31	104
Observed price	2023-02-20	100
Observed price	2023-02-24	99.4
Observed price	2023-03-16	95.5
Observed price	2023-03-24	90.9
Observed price	2023-04-09	98.8
Observed price	2023-04-17	99.9
Observed price	2023-05-03	95.9
Observed price	2023-05-07	95.6
Observed price	2023-05-27	90.5
Observed price	2023-06-04	90.1
Observed price	2023-06-20	94.8
Observed price	2023-06-28	96.2
Observed price	2023-07-14	100
Observed price	2023-07-30	99.4
Observed price	2023-08-07	96.9
Observed price	2023-08-11	96.6
Observed price	2023-08-23	94.1
Observed price	2023-09-20	97.7
Observed price	2023-09-24	93.0
Observed price	2023-10-02	91.4
Observed price	2023-10-10	94.0
Observed price	2023-10-22	91.7
Observed price	2023-10-30	89.4
Observed price	2023-11-15	91.7
Observed price	2023-11-27	94.2
Observed price	2023-12-09	91.7
Observed price	2023-12-17	94.8
Observed price	2024-01-06	95.4
Observed price	2024-01-22	92.4
Observed price	2024-02-03	92.5
Observed price	2024-02-15	89.0
Observed price	2024-02-19	89.5
Observed price	2024-03-10	93.7
Observed price	2024-03-18	94.8
Observed price	2024-04-03	91.0
Observed price	2024-04-15	88.6
Observed price	2024-04-23	97.7
Observed price	2024-05-01	96.0
Observed price	2024-05-21	100
Observed price	2024-05-29	99.7
Observed price	2024-06-06	104
Observed price	2024-06-22	101
Observed price	2024-07-04	102
Observed price	2024-07-12	105
Observed price	2024-08-01	116
Observed price	2024-08-05	115
Observed price	2024-08-25	121
Observed price	2024-09-10	127
Observed price	2024-09-18	121
Observed price	2024-09-30	121
Observed price	2024-10-08	119
Observed price	2024-10-16	121
Observed price	2024-10-24	133
Observed price	2024-11-09	124
Observed price	2024-11-29	132
Observed price	2024-12-03	131
Observed price	2024-12-23	123
Observed price	2025-01-04	122
Observed price	2025-01-12	118
Observed price	2025-01-20	123
Observed price	2025-02-09	146
Observed price	2025-02-17	150
Observed price	2025-02-25	157
Observed price	2025-03-13	150
Observed price	2025-03-29	157
Observed price	2025-04-06	150
Observed price	2025-04-22	165
Observed price	2025-05-08	173
Observed price	2025-05-12	165
Observed price	2025-05-20	174
Observed price	2025-06-05	182
Observed price	2025-06-13	184
Observed price	2025-07-03	177
Observed price	2025-07-07	181
Observed price	2025-07-27	162
Observed price	2025-08-04	163
Observed price	2025-08-20	173
Observed price	2025-08-24	169
Observed price	2025-09-05	162
Observed price	2025-09-25	164
Observed price	2025-10-03	153
Observed price	2025-10-11	160
Observed price	2025-10-31	145
Observed price	2025-11-04	147
Observed price	2025-11-24	157
Observed price	2025-11-28	157
Observed price	2025-12-06	148
Observed price	2026-01-07	155
Observed price	2026-01-11	164
Observed price	2026-01-19	168
Observed price	2026-02-04	180
Observed price	2026-02-08	182
Observed price	2026-02-24	187
Observed price	2026-03-04	179
Observed price	2026-03-20	163
Observed price	2026-03-28	164
Observed price	2026-04-17	157
Observed price	2026-04-21	161
Observed price	2026-05-11	183
Observed price	2026-05-15	192
Observed price	2026-06-04	175
Observed price	2026-06-08	176
Observed price	2026-06-12	184
Observed price	2026-07-14	176
Observed price	2026-07-22	194
Observed price	2026-07-26	195
Observed price	2026-08-11	186
Observed price	2026-08-27	190
Observed price	2026-09-04	183
Observed price	2026-09-12	192
Observed price	2026-09-21	187
Observed price	2026-09-25	190
Published advisor forecast	2026-09-18	189
Published advisor forecast	2026-12-18	185
Published advisor forecast	2027-03-18	190
Published advisor forecast	2027-06-18	194
Published advisor forecast	2027-09-18	192
Published advisor forecast	2027-12-18	198
Published advisor forecast	2028-03-18	202
Published advisor forecast	2028-06-18	204
Published advisor forecast	2028-09-18	208
Published advisor forecast	2028-12-18	212
Published advisor forecast	2029-03-18	214
Published advisor forecast	2029-06-18	219
Published advisor forecast	2029-09-18	214
Published advisor forecast	2029-12-18	219
Published advisor forecast	2030-03-18	223
Published advisor forecast	2030-06-18	225
Published advisor forecast	2030-09-18	230
Published advisor forecast	2030-12-18	232
Published advisor forecast	2031-03-18	237
Published advisor forecast	2031-06-18	239
Published advisor forecast	2031-09-18	241

2. Scenarios & Signals

Bull case

The bull case activates the day the FDA clears IQOS ILUMA. Authorization would convert a stalled US business into a genuine second growth leg, validating the smoke-free narrative just as a completed Fed cycle lowers the discount rate on defensive cash flows. Sequentially, ZYN destocking ends, US gross profit inflects, currency-neutral accelerates past 10%, and a weakening dollar amplifies translation. The multiple holds near 22x on far larger earnings, delivering equity returns well above the base path.

Bear case

The bear case begins where the H1 2026 US numbers already point. Promotional defence against VELO, Rogue and ALP permanently resets ZYN's margin; ILUMA slips again; and European excise harmonisation removes the smoke-free tax advantage. Currency-neutral decelerates toward 4%, refinancing at higher coupons erodes the remainder, and investors reclassify PM from growth staple to yield instrument. The multiple converges toward BAT's low-teens rating, and the shares de-rate faster than earnings grow.

Current crowd narrative

The settled belief: PMI has escaped tobacco's gravity and become a smoke-free growth company deserving a staples multiple. Ten buys against two holds, an average target near $206-207 and a 22.7x forward rating encode that conviction [15][17]. The anchoring bias is the 2023-2025 re-rating itself; investors extrapolate ZYN's explosive early adoption while treating the H1 2026 US gross-profit collapse as a destocking footnote rather than a competitive signal.

Alpha-gap assessment

The crowd modestly overestimates these shares. Two pieces of evidence point the same way: US adjusted gross profit fell 27.6% in H1 2026 while shipments rose [1], meaning price and promotional intensity, not inventory, are doing the damage; and the trailing 27x rating already embeds an ILUMA authorization that has sat undecided for 32 months [5]. The blind spot is duration — investors are paying a growth multiple for an algorithm whose highest-margin leg is being competed down while refinancing costs rise against negative book equity.

Convergence catalyst

Watch the Q4 2026 and FY2027 guidance in early February 2027. If US smoke-free gross profit fails to inflect and management guides currency-neutral below 8%, the premium to the 18.8x five-year median begins unwinding. The first sign is target-price trimming toward $195 while earnings estimates hold.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.3
Expected volatility regime: moderate
Convergence-cycle position: momentum

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Inelastic Demand Meets Annual Price HIKE	Follow the pricing evidence: Q2 2026 net revenues rose 10.4% to $11.2B with organic growth of 7.6% while cigarette volumes declined only 2-3% [1][2]. Addicted demand plus a consolidated ex-US oligopoly lets PMI push mid-to-high single-digit price/mix through every excise cycle, converting shrinking sticks into growing gross profit. This mechanism has survived four decades of decline and should persist, though management already flags moderating second-half combustible pricing.	Not available	+32.0%
Smoke FREE MIX Lifts THE Margin POOL	Heated tobacco volume grew 7.6% to 41.8 billion units in Q2 2026 [9], and IQOS/ZYN carry structurally richer gross margins than cigarettes, which is why group gross margin reached 67.1% in FY2025. As smoke-free approaches the majority of net revenue, each converted smoker raises revenue per consumer and reduces excise leverage. The effect compounds through the horizon, but is diluted by heavier US commercial investment.	Not available	+24.0%
Dividend Ratchet PLUS Quiet Deleveraging	The Board raised the quarterly dividend 8.8% to $1.60 on 18 September 2026, the eighteenth consecutive annual increase since the 2008 spin [13]. Against guided FY2026 operating cash flow of roughly $13.5B and capex of $1.4-1.6B [4], roughly $12B of free cash flow funds about $10B of dividends and steady Swedish Match debt paydown. That forward yield near 3.4% anchors valuation and attracts income mandates in a tightening rate regime.	Not available	+10.0%
FDA Paperwork AS Competitive MOAT	On 30 June 2026 the FDA granted Modified Risk Tobacco Product authorization to twenty ZYN variants, the first and only such clearance in nicotine pouches [9], and reauthorized IQOS exposure-modification claims through April 2031 [11]. Regulatory barriers that cost competitors years and hundreds of millions of dollars protect PMI's price premium and shelf position. This advantage persists so long as the FDA maintains its current PMTA architecture rather than a category-wide flavor rule.	Not available	+9.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
BOND Proxy Meets A FIVE Percent Tenor	The decisive number is the multiple, not the earnings: PM trades near 27x trailing GAAP and roughly 22.7x FY2026 adjusted EPS against a 18.8x five-year median [18]. With fed funds at 3.75-4.00% and the US ten-year near 5.0%, a 3.4% yielding defensive compounder competes directly with risk-free paper. Mean reversion toward 18-19x subtracts far more than operating growth adds in the early quarters, and only fades if policy rates decline.	Not available	-25.0%
Zyn's American Stall	The contradiction at the centre of the file: US net revenues fell 16.1% in H1 2026 and US adjusted gross profit dropped 27.6%, even as ZYN shipments rose 1.8% [1]. Management blames destocking, but VELO, Rogue, LOOP and newly launched ALP are all pricing into the category [8], and PMI is now accelerating US commercial spending. Promotional defence of share converts a high-margin growth asset into a cost centre, compressing group incrementals.	Not available	-9.0%
Europe Writes THE Excise Rulebook	The pending EU Tobacco Excise and Products Directive revisions threaten to harmonise heated-tobacco and pouch taxation upward, attacking precisely the margin pool that justifies PMI's premium rating. Poland's flavour ban and Japan's excise-driven price increase are already flagged as transient headwinds [23]. Regulation rarely reverses; once smoke-free products lose their preferential excise treatment, the conversion economics that underpin the 2030 ambitions weaken permanently across PMI's largest profit region.	Not available	-8.0%
Negative Equity Serial Refinancing	Book equity stood at minus $9.99B at FY2025 with a 0.96 current ratio and 0.42 quick ratio; interest coverage of 9.75x is comfortable but was built on pre-2022 coupons. PMI must roll a Swedish Match-swollen debt stack, unconditionally guaranteed by the parent [5], into a market pricing five-year money hundreds of basis points higher. Each refinancing tranche is a permanent, mechanical deduction from adjusted EPS growth.	Not available	-6.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Iluma Clears THE FDA GATE	Bundled PMTAs and MRTPAs for IQOS ILUMA were submitted in October 2023 and accepted in March 2024; at the 30 June 2026 10-Q no decision had been issued, roughly 32 months on [5]. Authorization, plausibly during 2027-2028, would unlock an at-scale US heated-tobacco launch against a 10% share ambition worth roughly $7B in retail value [24]. The market would re-rate growth duration, not just next year's EPS. It stays below even odds because ILUMA's induction system is novel and prior reviews averaged 718 days from a simpler baseline [12].	38.0%	+20.0%
Dollar Reversal PLUS Buyback Restart	PMI earns almost nothing in its reporting currency, so a sustained dollar downcycle mechanically inflates translated earnings; $0.15 of FY2026 guided EPS growth is already currency [1]. Should the Fed's tightening cycle end and the dollar weaken through 2028-2029 while ZYN US economics normalise, free cash flow of roughly $12B could fund the first meaningful repurchase since 2022 alongside the dividend. Combined FX translation and share-count reduction would deliver consecutive guidance raises. Probability stays moderate because dividend growth and deleveraging currently absorb nearly all free cash flow.	32.0%	+14.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Washington BANS Pouch Flavours	A federal flavour restriction or a punitive excise on oral nicotine would strike the highest-margin, fastest-growing line in the portfolio precisely where PMI has concentrated its acquisition capital. Swedish Match was purchased for its ZYN franchise; a 2028-2030 rulemaking that limits flavours to tobacco and menthol would gut US volumes, trigger goodwill impairment and collapse the growth premium embedded in the multiple. It remains below even odds because the current FDA has instead granted ZYN MRTP status [9], signalling harm-reduction sympathy rather than prohibition.	18.0%	-24.0%
Smoke FREE Growth Algorithm Breaks	Watch for two consecutive quarters where heated-tobacco volume growth falls below 4% while US smoke-free gross profit keeps contracting from the 27.6% H1 2026 decline [1]. That combination, most plausible in 2027-2028 if Japanese excise increases bite and European flavour bans spread, would prove the re-rating was borrowed against a story rather than an engine. Adjusted EPS growth would slip toward 4-5% and the multiple would compress toward the low teens where BAT trades [19]. It stays under 50% because ex-US IQOS conversion remains broad-based.	30.0%	-22.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_61b02a7d-0153-559d-b3ec-9cd61d94dfe8__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-2.0%	184.85	Q3 results in late October confirm continued US smoke-free gross-profit erosion while combustible pricing moderates as guided. With the ten-year near 5%, income buyers demand a wider spread; modest de-rating outweighs the fresh 8.8% dividend increase.
2	March 18, 2027	+3.0%	190.39	February FY2027 guidance of high-single-digit currency-neutral EPS growth steadies sentiment, and defensive rotation resumes as equity markets digest a further Fed hike. ZYN destocking laps out, restoring reported US shipment growth optics.
3	June 18, 2027	+2.0%	194.20	Q1 2027 delivers organic revenue growth near 6% with heated tobacco volumes compounding across Europe and Japan. Inflation-linked pricing power looks attractive as investors reprice staples against still-elevated consumer prices.
4	September 18, 2027	-1.0%	192.26	Continued FDA silence on ILUMA past the four-year mark drains patience from the US optionality trade, while accelerated commercial spending behind ZYN visibly compresses incremental margins in the second-quarter print.
5	December 18, 2027	+3.0%	198.03	A peaking policy rate and a stabilising ten-year yield relieve bond-proxy pressure. The annual September dividend increase near 7% plus a Q3 beat driven by ex-US price/mix restores modest multiple support.
6	March 18, 2028	+2.0%	201.99	FY2027 results confirm adjusted EPS near $9.2 and management reiterates the mid-term algorithm. Slowing US growth is now priced; the market pays for cash-flow reliability rather than for the smoke-free growth story.
7	June 18, 2028	+1.0%	204.01	European excise consultations on heated tobacco and pouches enter formal drafting, capping upside. Earnings progress continues, but investors discount a structurally higher future tax burden on the smoke-free margin pool.
8	September 18, 2028	+2.0%	208.09	Free cash flow near $13B and slower debt growth improve coverage ratios. Easing financing conditions allow PMI to refinance maturities at narrower spreads, removing one identified drag on adjusted earnings growth.
9	December 18, 2028	+2.0%	212.25	Smoke-free revenue crosses a symbolic majority of the group total, strengthening ESG-constrained buyer participation. Combined with another dividend increase, the yield floor lifts in absolute dollar terms and supports the price.
10	March 18, 2029	+1.0%	214.37	FY2028 guidance normalises toward 6-8% currency-neutral EPS growth as combustible volume decline steepens in Indonesia and Turkey. Earnings compound, but the market grants no further multiple expansion.
11	June 18, 2029	+2.0%	218.66	Improved cash conversion and reduced net leverage open room for a modest repurchase authorisation alongside the dividend. Per-share accretion from a shrinking count adds incrementally to operating earnings growth.
12	September 18, 2029	-2.0%	214.29	A European excise directive or a national flavour restriction lands, forcing downward revision to smoke-free margin assumptions. Investors mark down the growth premium even as headline earnings meet expectations for the quarter.
13	December 18, 2029	+2.0%	218.57	Pricing offsets absorb the new excise burden within two quarters, demonstrating the pass-through mechanism again. Confidence in the regulatory-resilience argument returns and the shares recover most of the prior quarter's loss.
14	March 18, 2030	+2.0%	222.94	FY2029 results show adjusted EPS approaching $11 with capex still under 4% of revenue. High free-cash-flow conversion in a lower-rate environment makes the roughly 3.5% yield competitive again against government paper.
15	June 18, 2030	+1.0%	225.17	Growth decelerates as the easiest IQOS conversion markets mature; Japan and Italy penetration plateaus. The stock trades as a mid-single-digit compounder with a reliable payout rather than a re-rating candidate.
16	September 18, 2030	+2.0%	229.68	The April 2031 expiry of IQOS exposure-modification orders forces an early renewal decision; a favourable signal from the FDA removes a known overhang and supports a modest valuation improvement.
17	December 18, 2030	+1.0%	231.97	Another high-single-digit dividend increase extends the twenty-plus-year record. Absent fresh catalysts, price appreciation tracks earnings growth minus continued gentle multiple normalisation toward the long-run median.
18	March 18, 2031	+2.0%	236.61	FY2030 results confirm the algorithm held through a full regulatory and rate cycle. Stable mid-to-high single-digit EPS growth with low capital intensity justifies a settled 18-19x rating on forward earnings.
19	June 18, 2031	+1.0%	238.98	Next-generation pouch and heated formats from competitors keep category pricing competitive. PMI defends share through scale and regulatory clearances, delivering steady rather than accelerating profit growth this quarter.
20	September 18, 2031	+1.0%	241.37	The horizon closes with adjusted EPS near $12 and the shares trading around 18-19x forward earnings. Returns over five years came principally from compounding and dividends, not multiple expansion.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Philip Morris International (NYSE: PM) details Q2 2026 results and EPS outlookstocktitan.net
[2]Philip Morris International Reports 2026 Second-Quarter & First Six-Months Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;finance.yahoo.com
[3]Philip Morris International (PM) Q2 2026 Summary | Quartrquartr.com
[4]Markets Today on X: "Philip Morris $PM Q2 FY26 Results — July 22, 2026 🔹 Revenue: $11.2B (Est. $10.63B) 🟢; +10.4% YoY. 🔹 Adjusted EPS: $2.20 (Est. $2.05) 🟢; +15.2% YoY. 🔹 Reported EPS: $1.80; ‑7.7% YoY, impacted by $511M non‑cash RBH equity impairment. Q3 Guidance 🔹 Adj. EPS: $2.20–$2.2… / Xx.com
[5]Philip Morris International Inc. - Form 10-Q - FY2026sec.gov
[6]2FIRSTS | Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays2firsts.com
[7]ZYN Nicotine Pouches in 2026: Sales Numbers, Growth & What's Coming Nextthesnusoutlet.com
[8]PMI Q2 2026 Earnings Preview: ZYN Growth, FDA Milestone and What to Expectthesnusoutlet.com
[9]Philip Morris International (PMI): Q2 2026 Results - Tobacco Insidertobaccoinsider.com
[10]Why Did Philip Morris (PM) Rise After Cutting Its 2026 Profit Forecast Again?finance.yahoo.com
[11]Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Productpmi.com
[12]IQOS USA: FDA Review - Tobacco Insidertobaccoinsider.com
[13]Philip Morris International Inc. - Form 8-K - FY2026sec.gov
[14]Philip Morris - 16 Year Dividend History | PM | MacroTrendsmacrotrends.net
[15]Philip Morris stock gains as Q3 guidance and analyst support underpin sentimentad-hoc-news.de
[16]Philip Morris stock trades near recent highs as Q2 2026 earnings and guidance support valuationad-hoc-news.de
[17]Philip Morris International (PM) Stock Price & Overviewstockanalysis.com
[18]PM Looks 20.1% Overvalued on GF Value™ After Dividend Hikegurufocus.com
[19]4 Tobacco Stocks Turning Huge Cash Flow Into High-Yield Dividends - 24/7 Wall St.247wallst.com
[20]Philip Morris stock rises as 2026 outlook moves higherad-hoc-news.de
[21]Philip Morris International (PM) - Fundamental Analysis Report 2026 (Updated)deepresearchglobal.com
[22]PM Stock Analysis 2026 - Price Target, Hold Rating & DCF Valuation · A.L. Capital Advisoryalcapitaladvisory.com
[23]Philip Morris International (NYSE:PM) Full-Year Guidance Disappoints Despite Strong Q2 Earnings Beat | ChartMill.comchartmill.com
[24]IQOS: USA launch - Tobacco Insidertobaccoinsider.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Universal Investor — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

GPT-6 Astra

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.